{"brief_title": "A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment", "brief_summary": "The purpose of this study is to compare 2 combination drug therapies in HIV-infected patients who have never received anti-HIV treatment.", "detailed_description": "In this open-label study antiretroviral-naive patients are randomized to one of two drug regimens: Arm I: 141W94 (amprenavir), 1592U89 (abacavir), and Combivir (3TC/AZT tablet). Arm II: Nelfinavir and Combivir.", "condition": ["HIV Infections"], "intervention_type": ["Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Lamivudine/Zidovudine", "Abacavir sulfate", "Amprenavir", "Nelfinavir mesylate"], "criteria": "Inclusion Criteria Patients must have: - CD4 count > 50. - HIV RNA > 5,000. - No active AIDS (excluding CD4 count < 200). - Ability to comply with dosing schedule and protocol evaluations. Prior Medication: Allowed: - 3TC or any protease inhibitor, if < 1 week of therapy. - Other nucleoside analogs, if < 4 weeks of therapy. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions are excluded: - Active AIDS (not including CD4 count < 200). - Malabsorption syndrome affecting drug absorption. Concurrent Medication: Excluded: Enrollment in any other investigational drug protocol. Prior Medication: Excluded: Non-nucleoside reverse transcriptase inhibitors.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "abacavir", "mesh_term": ["HIV Infections", "Abacavir", "Zidovudine", "Lamivudine", "Lamivudine, zidovudine drug combination", "Nelfinavir", "Amprenavir"], "id": "NCT00002216"}